scholarly journals Esophagitis Dissecans Superficialis (EDS) Secondary to Hair Dye Ingestion: Case Report and Literature Review

2021 ◽  
Vol 11 (2) ◽  
pp. 185-189
Author(s):  
Eric Omar Then ◽  
Tyler Grantham ◽  
Michell Lopez ◽  
Madhavi Reddy ◽  
Vinaya Gaduputi
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Autoimmune Disorders ◽  
Pharmacologic Therapy ◽  
Esophageal Mucosa ◽  
Hair Dye ◽  
Esophageal Lesion ◽  
Chemical Irritants

Esophagitis dissecans superficialis (EDS) is a rare and underdiagnosed esophageal lesion characterized by sloughing of the esophageal mucosa that has been associated with medications, various autoimmune disorders, and exposure to some chemical irritants. Anatomically, EDS is most commonly seen in the middle and distal thirds of the esophagus. When present, EDS is best treated by discontinuing the offending agent and initiating pharmacologic therapy with proton pump inhibitors. Steroids may also be effective if the etiology is autoimmune in nature. Our case highlights a 65-year-old female diagnosed with EDS after incidental ingestion of hair dye containing resorcinol and para-phenylenediamine (PPD).

scholarly journals Refractory gastroesophageal reflux disease

2012 ◽  
Vol 49 (4) ◽  
pp. 296-301 ◽  
Author(s):  
Joaquim Prado P. Moraes-Filho
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Reflux Disease ◽  
Skin Diseases ◽  
Pharmacological Therapy ◽  
Genotypic Differences ◽  
Esophageal Mucosa ◽  
Refractory Gerd

CONTEXT: Gastroesophageal reflux disease (GERD) is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Its pathophysiology, diagnosis and treatment have frequently been analyzed but it is interesting to review some aspects of the GERD refractory patients to the proton pump inhibitors treatment. The treatment encompasses behavioral measures and pharmacological therapy. The majority of the patients respond well to proton pump inhibitors treatment but 20%-42% of them may not do so well. Patients who are unresponsible to 4-8 weeks' treatment with proton pump inhibitors (omeprazole, pantoprazole, rabeprazole, lansoprazole, esomeprazole, pantoprazole-Mg) might have so-called refractory GERD. RESULTS: In some cases the patients are not real refractory because either they do not have GERD or the disease was not correctly treated, but the term refractory is still employed. Although debatable, the Brazilian GERD Consensus based upon evidences recommends as first step in the diagnosis, the upper digestive endoscopy to exclude the diagnosis of peptic ulcer and cancer and in some cases identify the presence of esophageal mucosa erosions. CONCLUSIONS: The main causes of the so-called refractory GERD are: (1) functional heartburn; (2) low levels of adherence to proton pump inhibitors treatment; (3) inadequate proton pump inhibitors dosage; (4) wrong diagnosis; (5) co-morbidities and pill-induced esophagitis; (6) genotypic differences; (7) nonacid gastroesophageal reflux; (8) autoimmune skin diseases; (9) eosinophilic esophagitis.

scholarly journals Pantoprazole Induced Thrombocytopenia: a Case report

2018 ◽  
Vol 1 (2) ◽  
pp. 105-107 ◽  
Author(s):  
Deebya Raj Mishra ◽  
K. Dahal ◽  
P.P. Gupta
Keyword(s):  
Platelet Count ◽  
Case Report ◽  
Gastrointestinal Bleeding ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Upper Gastrointestinal Bleeding ◽  
Drug Induced ◽  
The Third ◽  
Upper Gastrointestinal

Proton Pump Inhibitors serve as the cornerstone of management of Upper Gastrointestinal bleeding. In Nepal, intravenous Pantoprazole is widely used. One of the rare complications of intravenous Pantoprazole is thrombocytopenia which may lead to paradoxical increase in bleeding possibility. Here, we present a 70 year old gentleman who presented with hematemesis and melena and was treated with IV Pantoprazole. The Platelet count started decreasing from the third day onwards following which the patient was switched to Rabeprazole on the fourth day. Platelet count subsequently normalized. Thus, drug induced thrombocytopenia is one of the rare complications that has to be kept in mind with the use of Pantoprazole.

scholarly journals Pantoprazole-Induced Delirium: Review of a Case and Associated Literature

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Anupriya Razdan ◽  
Ramaswamy Viswanathan ◽  
Alan Tusher
Keyword(s):  
Case Report ◽  
Drug Interactions ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Psychiatric History ◽  
Double Dose ◽  
Geriatric Population ◽  
Antiulcer Agents

Background. Proton pump inhibitors (PPIs) are frequently prescribed antiulcer agents in hospitals and are shown to be safer than H-2 blockers. We present a case report of PPI-induced delirium, regarding which not much has been written in the literature. Case Report. We present a case of a 93-year-old woman with no known past psychiatric history, who was hospitalized for syncope workup and who developed delirium after a double dose of pantoprazole. Discussion. Very few reports of PPI-induced delirium exist in the literature. In this case report, we attempt to highlight the mechanism of PPI induced delirium which in our case was most likely due to the primary effects of PPI and drug-drug interactions. Given the paucity of literature on this topic, we encourage further research into relationship between PPI and delirium and urge caution while using PPIs in geriatric population.

scholarly journals Extraesophageal signs of gastroesophageal reflux disease: otorhinolaryngologist’s view

2021 ◽  
Vol 93 (4) ◽  
pp. 521-525
Author(s):  
Elena Yu. Radtsig ◽  
Daniil I. Konstantinov
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Reflux Disease ◽  
Chondroitin Sulphate ◽  
Clinical Manifestations ◽  
Esophageal Mucosa ◽  
Allergenic Potential ◽  
Repairing Effect

The data on association between various pathologies of the ENT organs and gastroesophageal reflux disease (GERD) is analysed in the article. The variety of extraesophageal signs of GERD in children and adults is given, what is advisable to inform physicians of different specialties about the possibilities of antireflux therapy. These options are expanded with the emergence of a unique new drug, Alfasoxx. Its bioadhesive formula is based on hyaluronic acid and chondroitin sulphate thereby protecting the esophageal mucosa. Alfasoxx acts on the surface of the esophageal mucosa without penetrating into the systemic bloodstream and it also has a low allergenic potential, which has been confirmed by numerous studies. With its healing and repairing effect on erosive lesions of the esophageal epithelium, Alfasoxx in combination with proton pump inhibitors is more effective in achieving regression of clinical manifestations of the disease and improving patients quality of life (according to SF-36 questionnaire) compared to proton pump inhibitors monotherapy.

505 Impaired Esophageal Mucosa Integrity in Refractory Reflux Disease Patients on Proton Pump Inhibitors. A Role for Residual Acid Reflux?

2015 ◽  
Vol 148 (4) ◽  
pp. S-99
Author(s):  
Silvia Cocca ◽  
Ans Pauwels ◽  
Sabine Roman ◽  
Frank Zerbib ◽  
Michele Cicala ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Reflux Disease ◽  
Acid Reflux ◽  
Esophageal Mucosa

Mucosal Protective Compounds in the Treatment of Gastroesophageal Reflux Disease. A Position Paper Based on Evidence of the Romanian Society of Neurogastroenterology

2016 ◽  
Vol 25 (4) ◽  
pp. 537-546 ◽  
Author(s):  
Teodora Surdea-Blaga ◽  
Ion Băncilă ◽  
Daniela Dobru ◽  
Vasile Drug ◽  
Ovidiu Frățilă ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Reflux Disease ◽  
Position Paper ◽  
Esophageal Mucosa ◽  
Reflux Symptoms

Background & Aims: Gastroesophageal reflux disease (GERD) therapy is challenging and suppression of acid secretion or prokinetics do not cure all cases. Some drugs with protective action on the esophageal mucosa have been used alternatively or in association with proton pump inhibitors (PPIs) and/or prokinetics. The Romanian Society of Neurogastroenterology undertook an Evidence-Based analysis, from which this position paper evolved. Methods: We performed a systematic literature search in PubMed until October 2015, using the terms: sucralfate, guaiazulene, gaiazulene, dimethicone, alginate, antacids and gastroesophageal reflux. Forty-seven papers were included and analyzed. Several statements were elaborated regarding the use of these drugs in GERD. The evidence and recommendations were discussed between the authors. Results: There is evidence in the medical literature suggesting the benefit of these drugs in GERD. In patients with persistent or mild reflux symptoms antacids rapidly relieve heartburn. Alginate-antacid combination is superior both over placebo and antacids to treat mild reflux symptoms, and can be used to treat persistent reflux symptoms despite acid suppressant therapy. Sucralfate is superior over placebo in alleviating GERD symptoms and can be used as maintenance therapy. Guaiazulene-dimethicone improves the quality of life in patients with GERD. Conclusions: Drugs used to protect the esophageal mucosa against acid are useful in alleviating chronic heartburn, especially in patients with mild reflux symptoms. Abbreviations: CS: Chondroitin sulfate; DA: Double Action; EE : Erosive esophagitis ; GERD: Gastroesophageal reflux disease; HA: Hyaluronic acid; H2RA: Histamine 2 receptor antagonist; ITT: Intention to treat; IM: Irsogladine maleate; NERD: Non-erosive reflux disease; PPIs: Proton pump inhibitors; RCT: Randomized controlled trial; RDQ: Reflux disease questionnaire; QoL: Quality of life.

Sign in / Sign up

Export Citation Format

Share Document